• Screening for Nitrosamines in Pharmaceutical Products

Chromatography

Screening for Nitrosamines in Pharmaceutical Products

Feb 24 2020

Nitrosamine are carcinogenic compounds so need to be monitored to ensure unsafe levels are not found in consumer products.  Due to unsafe levels being found in a number of pharmaceutical products the EMA (European Medicines Agency) is requiring pharmaceutical companies to complete and submit a risk assessment by 26th March.  This means many pharmaceutical manufacturers will potentially need to screen their products for nitrosamine content.

The Ellutia 800 Series TEA is perfectly suited to nitrosamine detection thanks to is selectivity and sensitivity for Nitroso compounds. For testing of pharmaceutical drugs, The 800 Series TEA can be interfaced to a chemical stripping system that allows for rapid testing of ATNC (Apparent Total N-nitrosamine content).  This quickly gives an accurate result for the total nitrosamine content of a sample showing both volatile and non-volatile components. 

Any positive sample can then be further analysed by an 800 Series TEA interfaced to a GC where volatile nitrosamines such as NDMA (N-Nitrosodimethylamine) can be separated and quantified.

More information online


Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions

Events

Microbiology Society Annual Conference 2024

Apr 08 2024 Edinburgh 2024

analytica 2024

Apr 09 2024 Munich, Germany

ChemBio Finland 2024

Apr 10 2024 Helsinki, Finland

Analytica Anacon India & IndiaLabExpo

Apr 15 2024 Mumbai, India

Analitika Expo 2024

Apr 16 2024 Moscow, Russia

View all events